Bionovate Technologies picks up semanticom for international PR

CHAM, Switzerland and BERLIN, October 17, 2020 (GLOBE NEWSWIRE) – The Berlin PR agency wins the international PR and strategic corporate communication business of the medical device manufacturer Bionovate Technologies Corp. The company's shares are listed on Nasdaq OTC (OTCPK: BIIO).

Bionovate Technologies Corp. focuses on investing and marketing patents and licenses that bring health and lifestyle diagnostics to your smartphone. With a strong focus on digital transformation, the company intends to build an FDA-cleared ecosystem of medical devices, biosensors and mobile applications to convert tests previously only performed in physical laboratories into tests that can be performed by anyone with a mobile device can be carried out. Innovations in these areas are transforming some of the most promising, high growth opportunities in the medical device market worldwide.

Thanks to a recently concluded agreement, Bionovate will hold shares in the German health tech start-up Digital Diagnostics AG, which is currently developing a promising corona antigen rapid test and will launch it shortly.

Aleksandar Vucak, CEO of Bionovate: "semanticom has recognized expertise in the positioning and popular explanation of new technologies and has extensive experience in international public relations for start-ups. That is why we chose the Berlin agency."

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Bionovate Technologies Corp.
Gewerbestr. 10
6330 Cham, Switzerland "data-reactid =" 16 ">Bionovate Technologies Corp.
Gewerbestr. 10
6330 Cham, Switzerland

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Press contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
bionovate-pr@semanticom.eu "data-reactid =" 17 ">Press contact
Thomas Huber
semanticom GmbH
+49 30 275 80 81 11
bionovate-pr@semanticom.eu



Source link

Be the first to comment

Leave a Reply

Your email address will not be published.


*